According to the World Cancer Research Fund International, ovarian cancer is the eighth most frequent malignancy in women worldwide. In 2022, there were around 324,603 new cases of ovarian cancer across the globe. The lifetime risk of ovarian cancer for a woman is approximately 1 in 87. A woman has roughly a 1 in 130 lifetime probability of passing away from ovarian cancer. With a mere 29% 5-year survival rate, most cases (85%) are identified with either distant or regional stage illness. Several companies are engaged in research initiatives which is boosting the advanced ovarian cancer drug landscape significantly.
The Advanced Ovarian Cancer Drug Pipeline Report by Expert Market Research gives comprehensive insights into advanced ovarian cancer drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for advanced ovarian cancer. The report includes the analysis of over 100 pipeline drugs and 25+ companies. It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from advanced ovarian cancer.
The detailed analysis of each drug, drug class, clinical studies, phase type, molecule type, route of administration and ongoing product development activities related to advanced ovarian cancer are covered.
Recurrent head and neck squamous cell carcinoma is characterised by the relapse of malignant tumors that develop in the squamous cells lining the mucosal surfaces of the head and neck region. This cancer commonly recurs after the patient receives initial treatment, such as surgery, chemotherapy, or radiation therapy. Thus, there is a growing focus on accelerating the development of novel recurrent head and neck squamous cell carcinoma therapeutics and personalized treatment strategies to improve the quality of life and survival rates of the affected patients.
Pharmaceutical companies are actively developing immunotherapies, targeted treatments, and combination regimens to effectively combat the disease. Additionally, increased R&D funding and advancements in precision medicine, along with adherence to advanced ovarian cancer treatment guidelines, are likely to improve patient outcomes and support pipeline expansion in the coming years.
The Advanced Ovarian Cancer treatment landscape involves the use of drugs and medications, that are often used to manage pain, and inflammation associated with the condition. In addition, bone growth stimulators and vitamin D supplements are also used to support bone health and expedite healing. Healthcare providers follow a multidisciplinary approach to optimize patient recovery and ensure procedure success. Currently, oxycodone and methocarbamol are commonly used in Advanced Ovarian Cancer procedures. While oxycodone is an analgesic, methocarbamol is a skeletal muscle relaxant often prescribed post-operatively. Researchers are working on developing various drugs that help in manage the condition with higher efficacy.
Advanced Ovarian Cancer is reported as the seventh most common cancer diagnosis across the globe. As per Global Cancer Observatory estimates, around 890,000 new cases and 450,000 deaths are caused by this cancer each year, accounting for nearly 4.5% of cancer diagnoses and deaths.
This section of the report covers the analysis of advanced ovarian cancer drug candidates based on several segmentations including:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase:
By Molecule Type
EMR’s advanced ovarian cancer therapeutic assessment report covers 100+ drug analyses based on molecule type:
By Route of Administration
EMR’s pipeline assessment report covers 100+ drug analyses based on the route of administration:
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase I covers a major share of the total clinical trials for advanced ovarian cancer with 56 pipeline drugs in the respective phase.
The drug molecules categories covered under advanced ovarian cancer pipeline analysis include small molecule, monoclonal antibody, peptide, polymer, and gene therapy. Several trials are ongoing to assess the efficacy of small molecules. Studies that targeted monoclonal antibodies have been highly effective in the management of advanced ovarian cancer. The report provides a comparative analysis of the molecule type for each molecule in various phases of clinical trials for advanced ovarian cancer.
The EMR report for the advanced ovarian cancer drug insights covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed advanced ovarian cancer therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in advanced ovarian cancer clinical trials:
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for advanced ovarian cancer. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of advanced ovarian cancer drug candidates.
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for advanced ovarian cancer. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of advanced ovarian cancer drug candidates.
The trial evaluates the efficacy and safety of Avastin in patients with advanced ovarian cancer. The trial is sponsored by F. Hoffmann-La Roche AG and is currently under phase IV.
The study evaluates the safety of Avelumab for advanced ovarian cancer treatment. The trial is sponsored by Pfizer and is currently under phase III.
To assess the effectiveness of olaparib in patients with advanced ovarian cancer when combined with paclitaxel and carboplatin (AUC4) against paclitaxel alone (AUC6). The trial is sponsored by AstraZeneca plc and is currently under phase II.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Advanced Ovarian Cancer Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for advanced ovarian cancer. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into advanced ovarian cancer collaborations, regulatory environments, and potential growth opportunities within advanced ovarian cancer pipeline insights.
Global Psoriatic Arthritis Treatment Market
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Molecule Type |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share